Logo of Capital Market Authority (CMA)
The Capital Market Authority’s (CMA) board of directors approved BaraSeen Medical Co.’s planned initial public offering (IPO) of 3.3 million shares (representing 17.1% of capital) on the Nomu-Parallel Market. 
In a statement today, June 25, the CMA clarified that the offering will be limited to qualified investors, as defined in its regulations and rules, and that a prospectus will be published well in advance of the offering start date.
The approval is valid for six months from the board’s decision and will be deemed void if the company’s shares are not fully offered and listed within this period.
Established in 2021, BaraSeen Medical is a medical company specializing in the operation of the Patek X Cancer Radiotherapy Center, which is considered the first specialized center for radiotherapy services in the Kingdom.
Logo of Capital Market Authority (CMA)
The Capital Market Authority’s (CMA) board of directors approved BaraSeen Medical Co.’s planned initial public offering (IPO) of 3.3 million shares (representing 17.1% of capital) on the Nomu-Parallel Market.
In a statement today, June 25, the CMA clarified that the offering will be limited to qualified investors, as defined in its regulations and rules, and that a prospectus will be published well in advance of the offering start date.
The approval is valid for six months from the board’s decision and will be deemed void if the company’s shares are not fully offered and listed within this period.
Established in 2021, BaraSeen Medical is a medical company specializing in the operation of the Patek X Cancer Radiotherapy Center, which is considered the first specialized center for radiotherapy services in the Kingdom.
